Drug Profile
MK 8150
Alternative Names: MK-8150Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Merck & Co
- Class Antihypertensives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hypertension
Most Recent Events
- 01 May 2013 Merck completes a phase I trial in Hypertension in Belgium (NCT01656408)
- 09 Aug 2012 Merck initiates enrolment in a phase I trial for Hypertension in Belgium (NCT01656408)
- 24 May 2012 Phase-I clinical trials in Hypertension in Belgium (PO)